Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028 is registered in ClinicalTrials.gov with Century Therapeutics, Inc. as lead sponsor.

NCT NCT06255028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06255028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases
Lead sponsor
Century Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 6, 2025
Completion date
August 31, 2028
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis, idiopathic inflammatory myopathies, lupus nephritis, systemic lupus erythematosus